Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11532680 | 0.88 | TEAD4 (0.45) | PGRACHETDP1ALDH1A1LMNA | |
| SCHEMBL13232164 | 0.80 | PGR (0.42) | PGRALDH1A1KDM4EAOC3LMNA | |
| SCHEMBL11834697 | 0.80 | PGR (0.42) | PGRTDP1TSHRALDH1A1KDM4E | |
| SCHEMBL2452815 | 0.80 | ESR1 (0.50) | PGRTDP1TSHRALDH1A1KDM4E | |
| SCHEMBL11302427 | 0.78 | HPGD (0.44) | CHRNA7ACHETDP1TSHRALDH1A1 | |
| SCHEMBL1154594 | 0.78 | AOC3 (0.47) | PGRTDP1TSHRAOC3LMNA | |
| SCHEMBL3051159 | 0.78 | CYP1A2 (0.42) | PGRALDH1A1KDM4EAOC3ALOX5 | |
| SCHEMBL307896 | 0.78 | CHRNA7 (0.39) | CHRNA7ACHETDP1ALOX5CES2 | |
| SCHEMBL1932757 | 0.78 | CHRNA7 (0.39) | CHRNA7ACHETDP1ALOX5CES2 | |
| SCHEMBL12791298 | 0.78 | AOC3 (0.47) | PGRTDP1TSHRAOC3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3397629-B1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598 LTD (KY) | 2023-04-19 | — | — | EP | disclosed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2118094-B1 | GAMMA-LACTAMS FOR THE TREATMENT OF GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8362054-B2 | Therapeutic substituted lactams | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8278347-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-7482475-B2 | Therapeutic lactams | ALLERGAN, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20090016981-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-7439372-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| WO-2008100809-A1 | GAMMA-LACTAMS FOR THE TREATMENT OF GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080058397-A1 | 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | OLD DAVID W | 2008-03-06 | — | — | US | disclosed |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | ALLERGAN, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274658-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | PGR 3874/4885CHRNA7 4046/4885ACHE 58/4885 |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | PGR 312/4885CHRNA7 3349/4885ACHE 1913/4885 |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | PGR 3874/4885CHRNA7 4046/4885ACHE 58/4885 |
| US-20090016981-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | PGR 847/4885CHRNA7 3947/4885ACHE 38/4885 |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT2, GOT1, NME4 | PGR 327/4885CHRNA7 1256/4885ACHE 1313/4885 |
| US-20080058397-A1 | 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | PTGIS, PTGIR, PTGS1 | PGR 756/4885CHRNA7 383/4885ACHE 292/4885 |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | PGR 847/4885CHRNA7 3947/4885ACHE 38/4885 |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | PTGIS, PTGIR, PTGS1 | PGR 996/4885CHRNA7 865/4885ACHE 1030/4885 |
| US-20070265321-A1 | THERAPEUTIC COMPOUNDS | ACER2, SLC10A1, ASAH2 | PGR 1467/4885CHRNA7 3747/4885ACHE 812/4885 |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | PGR 312/4885CHRNA7 3349/4885ACHE 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.